ENTITY
SMARTSCORE: 3.2/5

Dogwood Therapeutics (DWTX US)

5
Analysis
Health CareUnited States
Dogwood Therapeutics, Inc. operates as a development-stage biotechnology. The Company develops novel therapeutics and sodium channel blocker to treat moderate-to-severe chemotherapy induced neuropathic pain, cancer pain, and other pain indications. Dogwood Therapeutics serves patients in the United States.
more
18 Mar 2025 15:00Issuer-paid

DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP Debt Conversion Strengthens Balance Sheet

On March 18, 2025, Dogwood Therapeutics, Inc. announced that the first patient was dosed in the Phase 2b HALT-CINP clinical trial of its lead...

Share
11 Nov 2024 19:00Issuer-paid

DWTX: Phase 2 Long COVID Results Expected Soon

On November 7, 2024, Dogwood Therapeutics, Inc. (DWTX) announced financial results for the third quarter of 2024 and provided a business...

Share
16 Oct 2024 01:40Issuer-paid

Dogwood Therapeutics, Inc. - DWTX: Virios Therapeutics Becomes Dogwood Therapeutics

On October 7, 2024, Virios Therapeutics, Inc. (VIRI) announced a business combination with privately-held Wex Pharmaceuticals, Inc. to form Dogwood...

Share
13 Aug 2024 16:00Issuer-paid

VIRI: Enrollment Complete in Phase 2a Long COVID Trial Results Expected in October 2024

On August 8, 2024, Virios Therapeutics, Inc. (VIRI) announced financial results for the second quarter of 2024 and provided a business update. The...

Share
13 May 2024 16:00Issuer-paid

VIRI: Results for Phase 2 Long COVID Trial Expected in 2H24

On May 10, 2024, Virios Therapeutics, Inc. (VIRI) announced financial results for the first quarter of 2024 and provided a business update. The...

Share
No more insights
x